Skip to main content

New Products: Agendia's ColoPrint

Premium

Agendia last week launched ColoPrint, a microarray-based test based on an 18-gene expression signature that can be used to predict the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.

According to the Dutch firm, ColoPrint provides a "definitive relapse risk assessment" for 100 percent of all stage II patients and "eliminates the gray area of indeterminate results" found in patients using clinical and pathologic factors such as T4-stage and microsatellite instability status.

Agendia offers ColoPrint as a service through its labs in Amsterdam and Irvine, Calif. Agilent Technologies manufactures Agendia's arrays.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.